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[57] ABSTRACT 
The novel compound, 3-hydroxy-N-methylpyrroli 
done, is effective as a transdermal enhancer for the 
absorption of drugs through the skin of humans and 
animals. The 3-hydroxy-N-methylpyrrolidone is pre 
pared from delta-butyrolactone which is converted to 
methyl 2,4-dibromobutyrate, this intermediate is re 
acted with methylamine to form N-methyl-2,4 
dibromobutyramide, this intermediate is converted to 
3-bromo-N-methyl-2-pyrrolidone by ring closure, and 
the 3-bromo-N-methyl-2-pyrrolidone is reacted with an 
alkaline earth metal carbonate or alkaline metal carbon 
ate to form 3-hydroxy-N-methyl-2-pyrrolidone. 
8 Claims, 3 Drawing Sheets 
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S-HYDROXY-N-METHYLPYRROLIDONE AND 
PREPARATION THEREOF 
TECHNICAL FIELD 
This invention relates to a new composition for drug 
delivery and more particularly relates to use of the 
compound 3-hydroxy-N-methylpyrrolidone as a trans 
dermal enhancer for the absorption of drugs into hu 
mans and animals by absorption through the skin. 
BACKGROUND ART 
Transdermal absorption is currently one of the fastest 
growing methods of drug delivery. Transdermal thera 
peutic systems‘ are self-contained dosage forms that, 
when applied to intact skin, deliver drug(s) at a con 
trolled rate to the systemic circulation. Advantages of 
using the transdermal route include: enhanced thera 
peutic efficacy, reduction in the frequency of dosing, 
reduction of side effects due to optimization of the 
blood-concentration versus time pro?le, increased pa 
tient compliance due to elimination of multiple dosing 
schedules, bypassing the hepatic “first-pass” metabo 
lism , avoiding gastrointestinal incompatibilities and 
providing a predictable and extended duration of activ 
ity. However, the main function of the skin is to act as 
a barrier to entering compounds. As a consequence, 
transdermal therapy has so far been restricted to a lim 
ited number of drugs that possess the desirable physio 
chemical properties for diffusion across the skin barrier. 
One effective method of overcoming the barrier func 
tion of the skin is to include a penetration enhancer in 
the formulation of a transdermal therapeutic system. 
See Barry, Brian W.: Dermatological Formulations: Per 
cutaneous Absorption (Dekker, New York, 1983); 
Bronough et al, Percutaneous Absorption, Mechanisms 
Methodology-Drug Delivery, (Marcel Dekker, New 
York, NY 1985); and Monkhouse et al, Transdermal 
drug delivery-problems and promises. Drug Dev. Ina’. 
Pharm., 14, 183-209 (1988). 
A penetration enhancer is a chemical compound that, 
when included in a formulation, temporarily increases 
the permeability of the skin to the drug allowing more 
of the drug to be absorbed in a shorter period of time. 
Several different types of penetration enhancers have 
been reported such as dimethylsulfoxide, n-decyl 
methyl sulfoxide, N,N-dimethylacetamide, N,N-dime— 
thylformamide, l-dodecylazacycloheptan-2-one 
(Azone), propylene glycol, ethanol, pyrrolidones such 
as N-rnethyl-Z-pyrrolidone (NMP) and surfactants. See 
Bronough et al, supra, and Stoughton et al, Azone: A 
New Non-toxic enhancer of percutaneous penetration. 
Drug Dev. Ind. Pharm., 9, 725-744 (1983). 
N-methyl-Z-pyrrolidone is a versatile solvent which 
is miscible with water, ethyl alcohol, ether, chloroform, 
benzene, ethyl acetate and carbon disul?de. N-methyl 
pyrrolidone has been widely used as a solvent in indus 
trial processes such as petroleum re?ning, GAF Corp.: 
“M-Pyrol (N-methyl-Z-pyrrolidone) Handbook”, GAF 
Corp., New York, 1972. It is currently used as a solubi 
lizing agent in topical and parenteral veterinary phar 
maceuticals and is now under consideration for use in 
products intended for humans, Wells, D. A. et a1: Dis 
position and Metabolism of Double-Labeled [3H and 
14C] N-methyl-Z-pyrrolidone in the Rat. Drug Met. 
Disps, 16, 243-249 (1988). Animal and human experi 
ments have shown very little irritation or sensitization 
potential. Ames type assays and chronic exposure stud 
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ies have not revealed any signi?cant toxicity, Wells et 
al, Mutagenicity and Cytotoxicity of N-methyl-Z-pyr 
rolidone and 4-(methyl amino) Butanoic Acid in the 
Salmonella/microsome Assay. J. Appl. T ox., 8, 135-139 
(1988). N-methylpyrrolidone has also been shown to be 
an effective penetration enhancer. Barry et al, Optirni 
zation of Bioavailability of Topical Steroids Penetration 
Enhancers Under Occlusion. J. Inv. Derm., 82, 49-52 
(1984); Akter et al, Absorption’l‘hrough Human Skin of 
Ibuprofen and Flurbiprofen; Effect of Dose Variation, 
Deposited Drug Films, Occlusion and the Penetration 
Enhancer N-methyl-Z-pyrrolidone. J. Pharm. Phar 
macoL, 37, 27-37 (1984); Holegaard et al, Vehicle Effect 
on Topical Drug Delivery IV. Effect of N-methylpyr 
rolidone and Polar Lipids on Percutaneous Transport. 
Int. J. Pharm., 43, 233-240 (1988); Sugibayashi et al, 
Effect of Several Penetration Enhancers on the Percu 
taneous Absorption of Indomethacin in Hairless Rat. 
Chem. Pharm. Bull, 36, 1519-1528 (1988); Bennett et al, 
Optimization of Bioavailability of Topical Steroids: 
Non-Occluded penetration Enhancers Under Thermo 
dynamic Control. J. Pharm. PharmacoL, 37, 298-304 
(1985); Sasaki et al, Enhancing Effect of Pyrrolidone 
Derivatives on Transdermal Drug Delivery. 1. Int. J. 
Pharm., 44, 15-24 (1988); Lee et al, Toxicity of N-meth 
yl-2-pyrrolidone (NMP): Tetratogenic, Subchronic and 
Two-Year Inhalation Studies, Fund. Appl. Tox., 9, 
222-235 (1987). 
There remains a need in the art of transdermal deliv 
ery for a penetration enhancer which is safe, effective, 
and provides advantages not known to penetration en 
hancers of the prior art. 
DISCLOSURE OF THE INVENTION 
It is accordingly one object of the present invention 
to provide a novel penetration enhancer for use in trans 
dermal drug delivery. 
A further object of the present invention is to provide 
as a novel chemical compound, 3-hydroxy-N 
methypyrrolidone having advantageous characteristics 
as a penetration enhancer in transdermal delivery sys 
terns. 
A further object of the invention is to provide meth 
ods for preparation of the novel penetration enhancer, 
3-hydroxy-N-methylpyrrolidone. 
A still further object of the present invention is to 
provide transdermal delivery systems which contain as 
a safe and effective penetration enhancer, 3-hydroxy-N 
methylpyrrolidone. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro~ 
ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention a novel pene 
tration enhancing compound, 3-hydroxy-N-methylpyr 
rolidone. 
There is also provided by this invention a method for 
preparation of 3-hydroxy-N-methylpyrrolidone which 
comprises conversion of delta-butyrolactone to methyl 
2,4-dibromobutyrate, conversion of the methyl-2,4 
dibromobutyrate to N-methyl-2,4-dibrornobutyrarnide, 
ring closure of the N-methyl-2,4-dibromobutyramide to 
form 3-bromo-N-methyl-2-pyrrolidone, and conversion 
of the 3-bromo-N-methyl-2-pyrrolidone to 3-hydroxy 
N-methyl-Z-pyrrolidone by reaction with alkali metal 
carbonate. 
4,973,708 
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The present invention also provides transdermal 
compositions comprising as the penetration enhancer, 
3-hydroxy-N-methyl-Z-pyrrolidone. The present inven 
tion also provides a method for delivery of drugs 
through the human skin which comprises preparation of 
a transdermal drug delivery system containing 3 
hydroxy-N-methylpyrrolidone as a penetration en 
hancer, and applying the transdermal composition to 
the human skin. 
BRIEF DESCRIPTION OF DRAWINGS 
Reference is now made to the accompanying draw 
ings wherein: 
FIG. 1 is a graph showing a comparison of the per 
cent penetration of 131I-labeled Clioquinol when deliv 
ered with S-hydroxy-N-methylpyrrolidone, N-methyl 
pyrrolidone, and without an enhancer; 
FIG. 2 is a graph showing the percent penetration of 
125I-labeled Clioquinol using 3-hydroxy-N-methylpyr 
rolidone, N-methylpyrrolidone, and without an en 
hancer; and 
FIG. 3 is an HPLC radiochromatogram of the 5 
chloro-8-hydroxy-7-[131I]-iodoquinoline, the drug 
chosen to test the penetration enhancing characteristics 
of the compound of the invention. 
BEST MODE FOR CARRYING OUT THE 
INVENTION 
It has been discovered according to this invention 
that 3-hydroxy-N-methylpyrrolidone, also known as 
3-hydroxy-N-methyl-2-pyrrolidone, is an effective pen 
etration enhancer when used in transdermal drug deliv 
ery systems. 3-hydroxy-N-methylpyrrolidone is a novel 
compound prepared according to methods described 
herein. In general, the compound is a white solid having 
a melting point of 71°»72“ C. and is of the following 
structural formula: 
This novel compound is prepared through a series of 
novel chemical steps, preferably using as the basic start 
ing material delta-butyrolactone. In a preferred proce 
dure, delta-butyrolactone is reacted with bromine in the 
presence of a bromide compound such as phosphorus 
tribromide and under an elevated temperature in the 
range of 75°-l25° C. In a preferred procedure, the bro 
mide compound and delta-butyrolactone are mixed 
with agitation and at an elevated temperature, liquid 
bromine is slowly added. The temperature may be con 
troled in the preferred range by the rate of addition of 
the bromine and by external heating. Preferably the 
amount of bromine added to the butyrolactone is in the 
molecular ratio of about 1:2. Bromine addition is 
stopped when HBr evolution becomes evident, after 
which the reaction mixture is cooled and combined 
with methanol. The resulting solution is then saturated 
with HCl gas, the methanol is removed and methyl-2,4 
dibromobutyrate is removed as a pale yellow liquid. 
In a second step of the reaction, the methyl-2,4 
dibromobutyrate is reacted with methylamine in an 
aqueous solution at a temperature of below ambient in 
order to form N-methyl-2,4-dibromobutyramide. Then 
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butyramide is then recovered and puri?ed to obtain the 
solid intermediate product. 
The N-methyl-2,4-dibromobutyramide is then con 
verted to 3-bromo-N-methyl-Z-pyrrolidone by reaction 
with akali metal alkoxide to effect ring closure. In this 
reaction, an alcoholic solution of the N-methyl-2,4 
dibromobutyramide is formed and freshly prepared 
alkali metal alkoxide, preferably sodium ethoxide, is 
added drop-wise to the mixture under an inert atmo 
sphere. After the reaction is complete, the mixture is 
?ltered and the alcohol removed under reduced pres 
sure. This solid intermediate is then purified to provide 
a yellow liquid intermediate product. 
The recovered 3-bromo-N-methyl-2-pyrrolidone is 
then converted to the 3-hydroxy-N-methyl-2-pyrroli 
done of this invention by reaction with an alkali metal 
or alkaline earth metal carbonate in a substantially stoi 
chiometric reaction and in an aqueous medium. Prefera 
bly the reactant is added to a solution of the 3-bromo-N 
methyl-Z-pyrrolidone under agitation and while heating 
in the range of 75°-l25° C. After the reaction is com 
plete, the 3-hydroxy-N-methylpyrrolidine white solid 
product is recovered and puri?ed. 
The following is a schematic showing this four-step 
reaction. 
Br 
(1) Brz CO1CH3 CHsNHz 
(Demon 9 < 9 
Br 
.. Z 
in 
_ NZ1(+)(_)OCZHS 
Br NH 
/ 
CH3 
1 
Br OH 
5 y: K2CO3 i y: 
% 5 % 
N 0 N 0 
l | 
CH3 CH3 
4 2 
As pointed out above, a penetration enhancer is a 
chemical compound which, when included in a trans 
dermal formulation, affects the skin of a human by in 
creasing permeability of the skin to allow more of a 
drug to be absorbed in a shorter period of time. The 
penetration enhancer is normally contained in a formu 
lation, called a transdermal composition, in combination 
with the appropriate drug to be delivered and other 
known components of the formulation. According to 
this invention, it has been discovered that the 3 
hydroxy-N-methylpyrrolidone provides unexpectedly 
improved effects as a penetration enhancer when incor 
porated into a transdermal formulation. As mentioned 
herein, N-methylpyrrolidone is a known penetration 
enhancer. In studies leading to this invention using the 
prior art compound, N-methyl-2-pyrrolidone, it was 
discovered that a major metabolite of N-methylpyrroli 
4,973,708 
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clone which is excreted in the urine is 3-hydroxy-N 
methyl-Z-pyrrolidone. The subsequent synthesis of this 
compound, and closer examination of physical proper 
ties of the compound, led to the present discovery that 
3-hydroxy-N-methylpyrrolidone possesses several ad 
vantages over similar compounds such as N-methylpyr 
rolidone as a penetration enhancer. Thus, 3-hydroxy-N 
methylpyrrolidone provides at least equal and often 
superior enhancement of transdermal absorption while 
exposing the body to a lower metabolic burden. Fur 
ther, 3-hydroxy-N-methylpyrrolidone is a “softer” 
xenobiotic to the body because no energy will be ex 
pended in metabolic processes after the compound’s 
absorption into the systemic circulation. Also, in view 
of the apparent safety of N-methylpyrrolidone, its 
major metabolite, 3-hydroxy-N-methylpyrrolidone, 
would be expected to have an even lower toxicity. 
The 3-hydroxy-N-methylpyrrolidone of this inven 
tion may be used as the penetration enhancer in any 
transdermal drug delivery system in which it is effec 
tive. It is considered that the 3-hydroxy-N-methylpyr 
rolidone is compatible with all known drugs which are 
systematically active and can be delivered in a trans 
dermal system to be absorbed by the body surface. As is 
known, a transdermal delivery system comprises or 
reservoir for the composition to be transferred includ 
ing the drug of choice, the carrier, and the penetration 
enhancer. In general, the reservoir will be contained 
between a backing member and a pressure-sensitive 
adhesive which enables the transdermal device to be 
applied to the skin. Transdermal delivery systems are 
well known in the art and described, for example, in U. 
S. Pat. Nos. 3,598,122, 3,797,494, and 4,230,105. It is 
considered according to the present invention that the 
penetration enhancer of this invention can be used in all 
such systems. 
In practicing this invention one can employ any sys 
temically active drug which will be absorbed by the 
body surface to which the transdermal bandage is ap 
25 
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plied, consistent with their known dosages and uses. Of 40 
course, the amount of drug necessary to obtain the 
desired therapeutic effect will vary depending on the 
particular drug used. Suitable systemic drugs include, 
without limitation, Anti-microbial agents such as peni 
cillin and tetracycline; Sedatives and Hypnotics such as 
pentabarbital sodium and phenobarbital; Psychic Ener 
gizers such as 3-(2-aminopropyl) indole acetate; tran 
quilizers such as reserpine, chloropromazine hydro 
chloride, and thiopropazate hydrochloride; Hormones; 
Antipyretics such as aspirin, salicylamide, and sodium 
salicylate; morphine and other narcotic analgesics; An 
tidiabetics, e.g., insulin; Cardiovascular Agents, e.g., 
nitroglycerin, and cardiac glycosides such as digitoxin, 
Anti-spasmodics such as atropine, and methscololamine 
bromide; Anti-malarials such as the 4-aminoquinolines; 
and Nutritional Agents such as vitamins, essential amino 
acids, and essential fats. 
Further, topically active drugs consistent with their 
known dosages and uses can be administered. Suitable 
drugs include without limitation: Antiperspirants, e.g., 
aluminum chloride; Deodorants, e.g., hexachlorophene, 
Astringents, e.g., tannic acid; Irritants, e.g., methyl 
salicylate, Keratolytics, e.g., benzoic acid; Antifungal 
Agents; Anti-inflammatory Agents; Anti-neoplastic 
Agents, And Antibacterial Agents. 
The above and other drugs can be present in the 
reservoir alone or in combination form with pharma 
ceutical carriers. The pharmaceutical carriers accept 
45 
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able for the purpose of this invention are the art known 
carriers that do not adversely affect the drug, the host, 
or the material comprising the drug delivery device. 
Suitable pharmaceutical carriers include sterile water; 
saline, dextrose; dextrose in water or saline; condensa 
tion products of castor oil and ethylene oxide combin 
ing about 30 to about 35 moles of ethylene oxide per 
mole of castor oil; liquid glyceryl triester of a lower 
molecular weight fatty acid; lower alkanols; oils such as 
corn oil; peanut oil, sesame oil and the like, with emulsi 
?ers such as mono-or di-glyceride of a fatty acid, or a 
phosphatide, e.g., lecithin, and the like; glycols; polyal 
kylene glycols; aqueous media in the presence of a sus 
pending agent, for example, sodium carboxymethylcel 
lulose; sodium alginate; poly(vinylpyrolidone); and the 
like, alone, or with suitable dispensing agents such as 
lecithin; polyoxyethylene stearate; and the like. The 
carrier may also contain adjuvants such as preserving, 
stabilizing, wetting, emulsifying agents and the like 
together with the penetration enhancer of this inven 
tion. 
The following examples are presented to illustrate the 
invention. However, it is not to be considered as limited 
thereto. In the examples and through the speci?cation, 
parts are by weight unless otherwise indicated. 
Example 1 
Synthesis of 3-hydroxy-N-methyl-Z-Pyrrolidone 
General 
Melting points were determined on a Fisher-Johns 
melting point apparatus and are uncorrected. H-NMR 
and C-NMR spectra were obtained using a Varian 
Gemini 200 MHz or Varian XL-300 300 MHz spec 
trometer. Mass spectra were run on a Kratos M550 TA 
mass spectrometer with a KratosDS90 data system. 
Infrared (IR) spectra were recorded on a Perkin-Elmer 
Ratio Recording spectrophotometer. Mioroanalysis 
were performed by Atlantic Microlab, Inc., Atlanta, 
Ga. 
Reactions were routinely followed by thin layer 
chromatography (TLC) using Whatman K6F silica gel 
plates. Spots were visualized by exposure to iodine 
vapor or uv lamp (254mm). Column chromatography 
was carried out using silica gel (Davidson Chemical, 
Baltimore, Md.). 
Materials 
Delta-Butyrolactone (Adrich, Cat. No. 810,360-8, lot 
2710BK, 99%), Bromine (J. T. Baker, Cat. No. 1-9760, 
lot 849381), Phosphorous tribromide (Aldrich, Cat. No. 
25,653-6, lot l4l3BM), methanol (Fisher, Cat. No. A 
412, lot 854027), Methylamine, 40 wt % solution in 
water (Aldrich, Cat. No. M2,775-l, lot 03804CT), abso 
lute ethanol (Midwest Solvents Company of 111.), potas 
sium carbonate (Aldrich, Cat. No. 20,961-9, lot 
04006BP, 99+%). 
A. Methyl 2,4-dibromobutyrate. 
Phosphorous tribromide (2.0 ml, 5.7 gm, 0.021 mole) 
was added to deltabutyrolactone (100.8 gm, 1.17 mole) 
and the mixture was heated to 100° C. while stirring. 
Bromine (30 ml, 93.4 gm, 0.59 mole) was slowly added 
dropwise beneath the surface of the liquid. The temper 
ature was controlled at 110°—ll5° C. by the rate of 
addition of bromine and an oil bath. Additional PBr3 
(1.0 ml, 2.85 gm, 0.011 mole) was added to the reaction 
vessel and bromine addition was then continued until 
4,973,708 
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HBr evolution was evident (approx. 25 ml, 80 gm, 0.49 
mole). The reaction mixture was stirred and cooled to 
room temperature and ?nally cooled in an ice bath. The 
mixture was combined with methanol (480 ml) and the 
resulting solution was saturated with HCl gm. The 
solution was allowed to stand overnight at room tem 
perature after which the methanol was removed under 
reduced pressure. The residue was dissolved in ether, 
washed with 5% sodium bicarbonate solution, dried 
over magnesium sulfate and ?ltered. The solvent was 
removed and the residue distilled under reduced pres 
sure to yield a clear pale yellow liquid, 2 (216.4 gm, 
71%); b.p. 80°—85° C. @2-3 mm of Hg, IR(neat) 1775, 
1735, 1470 and 1380-1130 cm-l; H—-NMR 
(CDC13)82.54 (q, 2H, —CH2—CHBr—), 3.55 (t, 2H, 
Br—-CH2--CH2—-), 3.81 (s, 3H, O—CH3), 4.56 (t, 1H, 
—CH2—CHBr—); C-—-NMR, decoupled (CDC13) 
29.60, 36,69, 43.24, 53.10, 169.77 ppm. Anal. calcd. for 
C5H302B1'2 (295.934): C, 23.10; H, 3.10. Found: C, 
23.39; H, 3.14%. 
B. N-Methyl-2,4-dibromobutyramide. 
Methyl 2,4-dibromobutyrate (50 gm, 0.192 mole) was 
mixed with 40 wt % methylamine in aqueous solution 
(20.0 ml, 7.22 gm, 0.232 mole) with stirring and cooling 
in an ice bath. The reaction mixture was stirred for 16 
hours at 5° C., chloroform (100 ml) was then added and 
the organic layer washed with water. The organic ex 
tract was dried over magnesium sulfate, ?ltered and the 
solvent removed. The crude product was puri?ed by 
column chromatography (silica gel, gradient elution 
hexane/chloroform to chloroform/ethylacetate) to 
yield an off~white solid, (25.4 gm, 51.7%): m.p. 42°—47° 
C. The compound was used in the next step without 
further puri?cation. A small portion was further puri 
?ed for elemental analysis; m.p. 48°—49° C. IR(KBr) 
3450, 1660, 1570, 1415, 1240 and 1210 cm-1;H-NMR 
(CDC13) 8 2.48 (in, 1H, —CH2-CHBr--), 2.79(m, 1H, 
—CH2~CHBy—-), (d, 3H, -—NH2-CH3—), 3.55 (t, 2H, 
Br—-CH2—CH2), 4.54 (dd, 1H, —CHBr—); 6.39 (s, 
broad, 1H, -——Ng-—CH3), C—NMR, decoupled 
(CDC13) 26.83, 30.27, 37.60, 48.26, 168.65 ppm. Anal. 
calcd. for C5H9NBr2O (258.949): C, 23.19; H, 3.50; N, 
5.41. Found: C, 23.53; H, 3.44; N, 5.29%. 
C. 3-Bromo-N-methyl-Z-pyrrolidone 
To a stirred solution of N-methyl-Z,4~dibromobutyra 
mide (25.9 gm, 0.1 mole) in 65 ml of dry ethanol, kept 
under nitrogen, was added dropwise an equimolar 
quantity of freshly prepared sodium ethoxide (2.3 gm 
Na in 50 ml ethanol) over 40 minutes. After two hours 
the mixture was ?ltered and the ethanol removed under 
reduced pressure. The residue was dissolved in chloro 
form and washed with water, then washed with satu 
rated aqueous NaCl. Removal of the solvent and distil 
lation under reduced pressure yielded a yellow liquid, 
(11.55 gm, 65.2%); b.p. 90°~94° C. @ 0.1-1 mm. IR( 
neat) 1700, 1495, 1440, 1405 and 1300 cm"1; H-NMR 
(CDC13) 8 2.32 (m, 1H, —CHg-CHBr—), 2.72 (sextet, 
1H, —Cg2-CHBr—), 2.90 (s, 3H, —N——CH_3), 3.32 (m, 
1H, N-CHg-CHQ-L 3.58 (m, 1H, N-—CH2-CH2—), 
4.42 (dd, 1H, ~CH2-CEB1'—); C-NMR, decoupled 
(CDC13) 33.6, 35.1, 44.2, 47.5, 171.5 ppm. Anal. calcd. 
for C5HgBrNO (178.03): C, 33.73; H, 4.53; N, 7.87. 
Found: C, 33.81; H, 4.52; N, 7.82%. 
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D. 3-Hydroxy-N-methyl-Z-pyrrolidone 
3'Bromo-N-methyl-2-pyrrolidone (2.0 gm, 0.011 
mole) was dissolved in 100 ml of puri?ed water. Potas 
sium carbonate (2.33 gm, 0.017 mole) was added while 
stirring and the mixture was heated to 100°—110° C. 
After 4 hours, the reaction mixture was poured onto ice 
and neutralized with 1% aqueous HCl. Water was re 
moved under reduced pressure and the residue ex 
tracted with boiling 95% ethanol. After removal of the 
solvent, the product was puri?ed by column chroma 
tography (silica gel, gradient elution using from chloro 
form to chloroform/ethylacetate/methanol) to yield a 
white solid, (0.754 gm, 58.5%); m.p. 7l°—72° C. IR( 
nujol) 3120(broad), 1670, 1400, 1305, 1270 and 1170 
cm—l; H-NMR (CDC13) == 1.98 (m, 1H, —-C1~I_2 
CHOH—-), 2.41 (m, 1H, —-C_H2——CHOH—), 2.84 (s, 
3H, —N—CH3), 3.30 (m, 2H, —CH2—-N-), 4.30 (trip 
let of doublets, 1H, —CH—OH), 5.18 (d, 1H, 
—~CHOH-—§O—-N—~) ppm. Partially decoupled and 
Z-dimensional HETCOR spectra support the assign 
ments as given. Anal. calcd. for C5H9NO1 (115.129): C, 
52.16; H, 7.88; N, 12.17%. Ms(70eV)—Extract molecu 
lar ion M+ calculated for 115.06332, Found: 115.0634. 
Fragmentation pattern: 86 (M-29); 54 (M-58); 42 (M-73). 
Example 2 
Radioiodination of 5-chloro~S-hydroxyiodoquinoline 
This example prepares the radioiodinated control, 
5-chloro-S-hydroxy-iodoquinoline to be used in tests 
described hereinafter to determine the effect of penetra 
tion of the 3-hydroxy-N-methylpyrrolidone of this in 
vention. 
Materials 
Sodium Iodide-125 (New England Nuclear NEZ 033, 
radiochemical and radionuclidic purity 99%), Sodium 
iodide-131 (New England Nuclear NEZ 035H, radio 
chemical and radionuclidic purity 99%), 5-chloro-8 
hydroxy quinoline hydrochloride (Aldrich, lot 3128LJ 
Cat No. 25,044-9), 5-chloro-8-hydroxy-7-iodoquinoline 
(Aldrich, lot 0513KL Cat. No. 22,406-5), Iodobeads 
(Pierce Chemical Company No. 28666). 
Synthesis of 5-chloro-8-hydroxy-7[125I]-Iodoquinoline 
An aqueous solution (0.1N NaOI-I) containing ap 
proximately one mCi of Na125I was diluted to 0.5 ml 
with methanol. Three iodobeads were added and the 
solution was left to stand for 5 minutes at room tempera 
ture. 5-Chloro-S-hydroxyquinoline (0.5 ml of a stock 
solution containing 200 ug/ml in methanol) was added 
and the reaction vessel was shaken occasionally for 30 
minutes. The iodobeads were then removed, 5-chloro-8 
hydroxy-7-iodoquinoline (5.0 ml of a stock solution 
containing 1 mg/ml in methanol) was added followed 
by 20.0 ml of puri?ed water. The resulting white precip 
itate was ?ltered and washed with water until the ?l 
trate activity was at background levels. The product 
was then dissolved in CH1C12 (10 ml), transferred to a 
25 ml pear shaped ?ask and the solvent removed under 
reduced pressure. Assay by uv spectroscopy at 256 nm 
showed that 4.84 mg of 5-chloro-8-hydroxy-7 
iodoquinoline were recovered. Speci?c activity approx 
imately 120 uCi/mg. 
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Synthesis of 5-ch1oro-8-hydroxy-7-[131I]-Iodoquinoline 
This compound was prepared by the same procedure 
described above using NamI. 
Assessment of Radiochemical Purity 
Analysis and identi?cation of radiolabeled 5-chloro 
8-hydroxy-7-iodoquinoline and determination of radio 
chemical purity was performed by HPLC. The HPLC 
system used consisted of the following components: 
isocratic pump (Altex model 110A, Berkley, Calif), 
?xed volume injector (Rheodyne model 7125, Cotari, 
Calif), Waters u-Bondapak TM C-18 reverse phase col 
umn (Waters Ass., Milford, Mass), uv detector (Waters 
model 440, Milford, Mass), Radiomatic Model ES 
stream splitter (Radiomatic Instruments and Chemicals, 
Tampa, Fla.), Radiomatic Model HP ?ow-through 
radioactivity detector (Radiomatic Instruments and 
Chemicals, Tampa, Fla), dual channel strip chart re 
corder (Linear Instruments Inc., model 858, Irvine, 
Calif). . 
Samples were introduced using a 50 ul ?xed volume 
injection loop. A mobile phase containing 70% metha 
nol (Fisher HPLC grade, lot 874675) and 30% 0.05 M 
phosphoric acid (Eastman, lot 620) was ?ltered using a 
0.22u ?lter, degassed under vacuum and delivered at a 
flow rate of 1.0 ml/min. After passing through the col 
umn, the mobile phase effluent passed through the uv 
detector set at 254 nm and was split by the stream split 
ter. A percentage of the effluent was sent to the flow 
through radioactivity detector and the remainder di 
verted to waste. This detector mixed scintillation cock 
tail (Scintiverse LC, Fisher) with the effluent in a ratio 
of 4:1 (v/v). The uv output was recorded on one chan 
nel of the strip chart recorder and the radioactivity 
output was recorded simultaneously on the second 
channel. 
Standards were prepared by dissolving 5.0 mg of 
unlabeled 5-chloro-8-hydroxy-7-iodoquinoline or 5.0 
mg of 5-chloro-8-hydroxyquinoline in 100 ml of mobile 
phase to make a ?nal concentration of 50 ug/ ml. Radio 
active samples were prepared by dissolving the reaction 
product (4.84 mg) in methanol, taking a small aliquot 
(100 ul), evaporating and reconstituting in mobile phase. 
The retention time for 5-chloro-8-hydroxy-7 
iodoquinoline was 10.5 minutes. 5-chloro-8-hydrox 
yquinoline eluted with the solvent front at 3 minutes. 
. An HPLC chromatogram for 5-chloro-8-hydroxy-7 
[mm-iodoquinoline is shown in FIG. 3. In FIG. 3, the 
upper tracing represents UV detection of radioiodina 
tion product at 254 nm; A: solvent front/ 5~chloro-8 
hydroxyquinoline, B: 5-chloro-8-hydroxy-7~iodoquino 
line. Lower tracing represents radioactivity detection 
which was monitored continuously using a ?ow 
through liquid scintillation counter. Only one radioac 
tive peak (lower tracing) was detected that corresponds 
to the uv peak of 5-chloro-8-hydroxy-7-iodoquinoline. 
EXAMPLE 3 
In vitro penetration of radioiodinated 
5-chloro-8-hydroxy-7~iodoquinoline. 
General 
Standard Franz diffusion cells (15 mm i.d., o-ring 
design) were manufactured by Crown Glass Inc., Som 
erville, NJ. The cell caps were modi?ed with ground 
glass joints to ?t 14/20 ground glass stoppers. A Franz 
diffusion cell drive console F-DCD-9 was also manu 
factured by Crown Glass. A Vandercamp 2500 recircu 
15 
25 
30 
35 
45 
65 
10 
lating water bath was used to maintain the cells at 37° C. 
Split thickness human allograph tissues (0.015 in. thick 
ness), thigh back area, was obtained from the Tissue 
Transplant Bank, St. Agnes Medical Center, Philadel 
phia, Pa. Samples were counted in a Packard Auto 
Gamma Scintillation Spectrometer. 
Materials 
Sterile Saline (0.9% Sodium Chloride USP, Trave 
nol, NDC 0338-0049-04 lot co56747), Albumin (Bovine, 
fraction v, Sigma A-4503 lot l27F-0877), N-Methyl-Z 
pyrrolidone (Aldrich 99+ % Cat No. 24,279-9 lot 
04402TP), Neomycin Sulfate (Sigma N-l876 lot 66F 
0151), absolute ethanol (Midwest Solvents Company of 
Illinois). 
Procedure 
Human allograph tissue, which had been stored at 
—70° C., was thawed and immediately mounted in a 
Franz type diffusion cell. The receptor chamber was 
?lled with normal saline containing 2% albumin and 
0.05% neomycin sulfate. Each cell was maintained at 
37° C. and stirred at 600 rpm. After the cells had been 
allowed to equilibrate for 4 to 6 hours, 200 ul of a satu 
rated ethanolic solution of 5-chloro-8-hydroxy-7-[l251] 
iodoquinoline (approx. 70 uCi, 0.44 mg) was applied to 
the donor side of each cell. This was immediately fol 
lowed by either 200 pl of absolute ethanol for the con— 
trol cells, 200 pl of 50% (w/v 3-hydroxy-N-methylpyr 
rolidone in ethanol or an equimolar ethanolic solution 
of N-methylpyrrolidone (43.1% w/v). The cells were 
then capped with ground glass stoppers. At various 
time intervals, over an 80-100 hour period, the entire 
contents of the receptor chamber was removed with a 
10 cc syringe and placed into a vial. The receptor cham 
ber was then re?lled with fresh solution. After the last 
collection these vials were placed in a well-type gamma 
counter and counted for I-125 activity. 
At the time of dosing 200 pl of the saturated 5-chloro 
8-hydroxy-7-[um-iodoquinoline solution was placed 
into separate vials to calculate the amount of activity 
(dose) applied to the skin. 
EXAMPLE 4 
In this example, 3-hydroxy-N-methyl pyrrolidone 
was tested for its use as a percutaneous penetration 
enhancer. In vitro studies were carried out using Franz 
type diffusion cells. The penetration enhancing proper 
ties of 3-hydroxy-N-methylpyrrolidone was compared 
to N-methyl pyrrolidone, a compound known to en 
hance the penetration of drugs through the skin. 
For these in vitro studies radioiodinated 5-chloro-8 
hydroxy-7-iodoquinoline was ‘chosen as a model drug. 
This drug, known as Clioquinol USP, is currently mar 
keted by Ciba (Ciba Pharmaceutical Company, 556 
Morris Avenue, Summit, NJ. 07901), as a topical an 
tibacterial/antifungal agent trade named Vioform TM. 
It was chosen because (1) it is a drug that is absorbed 
very slowly through the skin and (2) Clioquinol inher 
ently has iodine in its structure, allowing easy prepara 
tion of a radiolabeled analogue. This radiolabeled 
marker is conveniently used to follow the penetration of 
the drug through the skin. 
Franz diffusion cells are designed to mimic in vivo 
conditions. A ?nite dose of drug is applied to the stra 
tum corneum side of the skin and penetration is fol 
lowed by analyzing for the drug in the receptor phase 
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underneath. In these studies the amount of drug cross 
ing the skin barrier is estimated by counting total radio 
activity in the receptor phase. While no excised tissue 
has been found to duplicate in vivo absorption in hu 
mans, excised human skin is generally regarded as the 
best substitute and was therefore used in these studies. 
In a preliminary study, the transdermal absorption of 
Clioquinol was evaluated in the presence of 3-hydroxy 
N-methylpyrrolidone, N-methylpyrrolidone, and in the 
absence of enhancer. An ethanolic solution of [L131] 
Clioquinol was applied to 3 cells followed by either 
ethanol (control), 50% 3-hydroxy-N-methylpyrroli 
done in ethanol or an equimolar solution of N-methyl 
pyrrolidone. In FIG. 1, the percent penetration of 5 
chloro-8-hydroxy-7-[131I]-iodoquinoline through 
human skin is illustrated. The amount of 5-chloro-8 
hydroxy-7-[131I]-iodoquinoline activity applied is equal 
to 100%. As shown in FIG. 1, the extent of enhance 
ment by 3-hydroxy-N-methylpyrrolidone is clearly evi 
dent. At 48.5 hours the amount of L131 Clioquinol that 
had penetrated through the skin in the presence of 3 
hydroxy-N-methylpyrrolidone (10.2% absorbed) was 
3.9 times greater than the control (2.6% absorbed) and 
1.5 times more than with N-methylpyrrolidone (6.5% 
absorbed). 
The study was repeated using I-l25 labeled Cli 
oquinol. Iodine-125 was used because the longer half 
life (t§=60d) and lower energy gamma ray (0.035 Mev) 
were better suited to our experimental design. The re 
sults are shown in FIG. 2. In FIG. 2, the percent pene 
tration of 5-chloro-8-hydroxy-7-[lzs?-iodoquinoline 
through the human skin is illustrated. The amount of 
5-chloro-8-hydroxy-7-[125I]~iodoquinoline applied is 
equal to 100%. The relative order of enhancement was 
found to be the same with 3-hydroxy-N-methylpyrro 
lone >N-methylpyrrolone>control. The amount of 
Clioquinol penetrating the skin in the presence of 3 
hydroxy-N-methylpyrrolidone (40.0% absorbed) was 
1.8 times higher than the control (19.5% absorbed) and 
1.3 times greater than with N-methylpyrrolidone 
(27.8% absorbed) at 85.5 hours. Alternatively, the same 
amount of Clioquinol was absorbed in approximately 32 
hours in the presence of 3-hydroxy-N-methylpyrroli 
done (19% absorbed) as was absorbed in 85 hours in the 
absence of 3-hydroxy-N-methylpyrrolidone. 
The results of these experiments indicate that 3 
hydroxy-N-methylpyrrolidone shows great potential 
for use as a percutaneous penetration enhancer. The 
absorption of Clioquinol was clearly increased in the 
presence of 3-hydroxy-N-methylpyrrolidone as com 
pared to its absorption in the presence of ethanol and 
N-methylpyrrolidone. In addition, since 3-hydroxy-N 
methylpyrrolidone is a major metabolite of N-methyl 
pyrrolidone, it should offer the advantage of being a 
lower toxicological burden to the body. 
The mechanism by which penetration enhancers 
exert their effects has not been clearly established. Pos 
sible modes of action that have been suggested include 
altering membrane ?uidity in the stratum corneum, 
altering the partitioning behavior of the drug between 
the stratum corneum and the underlying dermal tissues 
and solubilizing the lipid components of the stratum 
corneum. Most likely penetration enhancers work by a 
combination of these and other mechanisms with one 
mechanism being more dominant than others for a par 
ticular type of enhancer. Although the mechanism is 
not known, since 3-hydroxy-N-methylpyrrolidone ef 
fectively enhances the absorption of a poorly absorbed 
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compound like Clioquinol, this suggests that 3-hydroxy 
N-methylpyrrolidone will be effective for enhancing 
the percutaneous absorption of many other poorly ab 
sorbed compounds. 
In conclusion, a novel compound, 3-hydroxy-N 
methylpyrrolidone, was synthesized and was shown to 
effectively enhance the in-vitro absorption of a mode 
drug. Further, 3-hydroxy-N-methylpyrrolidone is 
shown to be more effective than N-methylpyrrolidone 
in enhancing the absorption of drugs. Because it is a 
metabolite, 3-hydroxy-N-methylpyrrolidone should be 
metabolically softer to the body and less irritating than 
other compounds such as N-methylpyrrolidone. The 
introduction of a potent, non-toxic and non-irritating 
compound that can effectively enhance the penetration 
of poorly absorbed drugs would open the way for the 
clinical use of transdermal therapeutic systems contain 
ing drugs that otherwise could not be administered by 
this route. 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid 
ered as limited thereto. 
We claim: 
1. The compound, 3-hydroxy-N-methylpyrrolidone 
of the formula 
2. A method for the preparation of 3-hydroxy-N 
methylpyrrolidone of the formula 
which comprises: 
(a) reacting delta-butyrolactone with bromine in the 
presence of a catalyst and at an elevated tempera~ 
ture to form methyl 2,4-dibromobutyrate; 
(b) reacting the methyl-2,4-dibromobutyrate with 
methylamine in an aqueous medium to form N 
methyl-2,4-dibromobutyramide; 
(c) reacting the N-methyl-2,4-dibromobutyramide 
with an alkali metal alkoxide to effect ring closure 
and form 3-bromo-N-methyl-2-pyrrolidone; and 
(d) reacting the 3-bromo-N-methyl-2-pyrrolidone 
with an alkali metal or alkaline earth metal carbon 
ate to form the 3-hydroxy-N-methylpyrrolidone. 
3. A process according to claim 2 wherein step (a) is 
carried out by reacting delta-butyrolactone with bro 
mine in the presence of phosphorus tribromide at an 
elevated temperature in the range of 75°—125° C. 
4. A process according to claim 2 wherein step (b) is 
carried out by reacting the methyl 2,4-dibromobutyrate 
with methylamine in an aqueous solution at a tempera 
ture of below ambient temperature. 
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5. A process according to claim 2 wherein step (c) is 
carried out by reacting the N-methyl-2,4 
dibromobutyramide with alkali metal alkoxide in an 
alcoholic solution under an inert atmosphere. 
6. A process according to claim 2 wherein step (d) is 
carried out by reacting the 3-bromo-N-methyl-2-pyr 
rolidone with an alkaline earth metal carbonate in a 
substantially stoichiometric reaction in an aqueous me 
dium at an elevated temperature of 75°—l25° C. 
7. A method for the preparation of the 3-hydroxy-N 
methylpyrrolidone of claim 1 which comprises reacting 
3-bromo-N-methyl-Z-pyrrolidone with an alkali metal 
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carbonate or alkaline earth metal carbonate in a substan 
tially stoichiometric reaction in an aqueous medium. 
8. A method for the preparation of the 3-hydroxy-N 
methyl-Lpyrrolidone of claim 1 which comprises react 
ing methyl 2,4-dibromobutyramide with an alkali metal 
alkoxide in an alcoholic medium to effect ring closure 
and form 3-bromo-N-methylpyrrolidone, and then re 
acting the 3-bromo-N-methylpyrrolidone with an alka 
line earth metal carbonate to form the S-hydroxy-N 
methyl-Z-pyrrolidone. 
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